Abel Hall LLC
ACAD icon

Abel Hall LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

Abel Hall LLC’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$257K Buy
12,765
+71
+0.6% +$1.91K 0.05% 521
2026
Q2 		$321K Sell
12,694
-1,561
-11% -$34.3K 0.06% 444
2026
Q1 		$317K Buy
14,255
+4,182
+42% +$100K 0.07% 383
2025
Q4 		$269K Buy
+10,073
New +$241K 0.06% 387

Other funds holding ACAD

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Abel Hall LLC's ACAD Position: Q3 2026 in Review

Abel Hall LLC increased its Acadia Pharmaceuticals (ACAD) stake by 0.56% in Q3 2026, buying an estimated $1.91K and bringing the position to 12,765 shares worth $257K. The position accounts for 0.05% of the portfolio, ranked #521.

Abel Hall LLC first reported a position in ACAD in Q4 2025 and has held it in 4 quarters since. The position peaked at $321K in Q2 2026. 263 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • Abel Hall LLC held 12,765 shares of Acadia Pharmaceuticals worth $257K as of Q3 2026.
  • Abel Hall LLC bought 71 Acadia Pharmaceuticals shares in Q3 2026, an estimated $1.91K.
  • Acadia Pharmaceuticals made up 0.05% of Abel Hall LLC's portfolio in Q3 2026, its #521 holding.
  • Abel Hall LLC first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Abel Hall LLC's Acadia Pharmaceuticals position peaked at $321K in Q2 2026.
  • 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on Abel Hall LLC's 13F filing for Q3 2026, filed 19 Oct 2026.